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IMPACT OF STORAGE CONDITIONS ON MARROW AND PERIPHERAL
BLOOD STEM CELL PRODUCTS STORED OVER 72 HOURS
Kao, G.1, Kim, H.1, Gatzo, L.1, Madison, H.1, Daley, H.1,
Perzepiorka, D.2, Burger, S.3, Kelley, L.4, Vierra-Green, C.5,
Flesch, S.5, Spellman, S.5, Miller, J.5, Confer, D.5. 1Dana Farber Cancer
Institute, Boston, MA; 2University of Tennessee Health Science Center,
Memphis, TN; 3Advanced Cell and Gene Therapy, LLC, Chapel Hill,
NC; 4University of Utah, Salt Lake City, UT; 5NationalMarrowDonor
Program, Minneapolis, MN.
Hematopoietic stem cell (HSC) transplants from unrelated do-
nors are routinely used to treat patients with hematologicmalignan-
cies. HSC products are usually collected off site and require
transport to the transplantation centers. The impact of transport
conditions on HSC graft composition during short-term storage
have not been well described. This study evaluated the short-term
handling and storage conditions for marrow and PBSC products.
The study examined five bone marrow (BM) and four G-CSF mo-
bilized peripheral blood stem cell (PBSC) products from healthy
volunteers. Products were stored at 4C or 20C (RT) for up to
72 hrs. Product samples were evaluated at 0,24,48 and 72 hours
for WBC, viability, proliferative potential (CFC assay), CD341
cells, monocytes (CD141) and lymphocyte subsets
(CD31,4,8,52,56,20) during storage. Descriptive statistics and
multivariate repeated measures analysis were performed for each
of the variables and product. Percent cell viability, CD341/ml and
stem cell content CFU-GM/106 at t5 0 through 72 hrs are summa-
rized in table 1. Cell viability, stem cell, monocytes and lymphocyte
(except for CD81 and CD201) content for PBSC products de-
creased during 72 hrs regardless of storage temperature (p 5
0.0001). The rate of degradation was worse in products stored at
RT (p# 0.001). For BM products; WBC, cell viability, CFU-
GM, and CD41 cell content decreased over 72 hrs with more
significant decreases in WBC and CFU for products stored at
RT. Unlike PBSC, BM products stored at RT did not have signif-
icantly lower HSC content or viability than BM products stored at
4oC. The number of viable CD341/ul was not affected by storage
condition over time for BM products, but the quality of HSC as
measured by CFU significantly deteriorated after 72 hrs (p 5
0.0001). The HSC quality as measured by changes in product white
blood cell count, viable CD341 cells, cell viability, CFU colonies,
monocytes and lymphocyte subsets during storage and betweenChanges in HSC Product Characteristics Over Time
t 5 0 t 5 24 t 5 48 t 5 72
Total 7 AADViability % *
PBSC
4C 94.2 91.9 85.8 72.1
20C 94.2 77.1 46.6 39.3
BM
4C 97.9 94.3 99.4 96.5
20C 97.9 91.8 93.1 93.8
CD341/ml % *
PBSC
4C 100.0 99.8 98.1 83.2
20C 100.0 71.4 19.0 4.6
BM
4C 100.0 110.6 74.1 77.6
20C 100.0 154.2 94.3 105.6
CFU-GM/106 % *
PBSC
4C 100.0 152.7 162.4 38.2
20C 100.0 61.8 9.7 0.0
BM
4C 100.0 87.0 32.6 26.1
20C 100.0 43.5 32.6 30.4
*Base line percentage at t 5 0 hrs.temperatures worsened over time regardless of storage condition.
The primary objective of the study was to generate data to precisely
define optimal and acceptable methods for handling of hematopoi-
etic stem cells prior to infusion. Therefore, refrigerated storage of
PBSC and BM products appears to optimize the quality and quan-
tity of the product. This is particularly relevant for PBSC products
that may require multiple days for collection and/or transport.252
MOBILIZATION OF MURINE HSCs WITH AMD15057, A SMALL MOLE-
CULE INHIBITOR OF CD49d (VLA4)
Ramirez, P.A., Rettig, M., Holt, M., Ritchey, J., DiPersio, J.F. Wash-
ington University, St. Louis, MO.
Background: Developing hematopoietic stem cells (HSC) are
largely confined to the bone marrow (BM) microenvironment.
AMD3100 is a bicyclam molecule that potently, selectively, and re-
versibly antagonizes the binding of SDF-1 to CXCR4, and is the
most promising mobilizing agent currently in clinical development.
Significant data also support the role of VCAM1/VLA-4 axis in
HSC homing and mobilization. In this study, we compared the ki-
netics and efficacy of HSC mobilization by AMD15057, a small
molecule inhibitor of VLA-4, to AMD3100 and GCSF.Methods:
To evaluate the mobilization of HSC progenitors, 8 week old 129/
B6 F1 mice (n 5 6 per group, 3 experiments) were left untreated
(unmobilized) or treated with AMD15057 (1 mg/kg iv),
AMD3100 (5 mg/kg sc), G-CSF (250 mg/kg/day  5 days) or the
combination of AMD15057 and AMD3100. Total WBC and
CFU-GM were determined at different time points for each mobi-
lization regimen. For long-term competitive repopulation cell as-
says (LTRC), PBMCs from 3 CD45.21 unmobilized or mobilized
mice (700 uL PB each) were pooled, mixed with a fixed number
of 5  105 CD45.11 BM mononuclear cells (MNC) (3:1 ratio)
and injected into lethally irradiated CD45.11/CD45.21 recipient
mice. Chimerism was evaluated 18, 30, and 60 days after transplan-
tation by flow cytometry. Results: A single iv injection of
AMD15057 resulted in maximummobilization of CFU-GMwithin
1 h compared to 3 h after AMD3100. Dramatic synergism of CFU-
GM mobilization (120 fold over baseline) was seen when
AMD15057 was combined with AMD3100. Furthermore, the com-
bination of AMD15057 plus AMD3100 induced essentially equal
mobilization of long term marrow competitive repopulating
HSCs compared to GCSF treated donors (Table 1). Overall sur-
vival at 60 days after transplantation was 100% for all cohorts, ex-
cept for the unmobilized PB group (80% survival). Conclusions:
Rapid mobilization of CFU-GM cells can be induced by
AMD15057. AMD15057 synergized with AMD3100 to mobilize
long term marrow repopulating HSCs. These results show that
the VCAM1/VLA-4 axis is involved in HSC and progenitor cells
trafficking and retention in the bone marrow microenvironment.
Table 1. Percentage of CD45.2 donor cells in heterozygous recipients
Unmobilized AMD150571PB AMD15057 AMD3100 AMD3100 G-CSFDay 1 18 13 25 39 60 71Day 1 30 11 36 46 64 78Day 1 60 14 40 50 67 82253
DIMINISHED BIOLOGICAL POTENCY OF BM-DERIVED CD1331 CELLS
OBTAINED FROM PATIENTS WITH CORONARY ARTERY DISEASE IN
IN VITRO AND IN VIVO STUDIES
Greco, N.J., Finney, M., Joseph, M., Hammond, L.R., Forester, M.,
Bhakta, S., Goldberg, J., Scheid, P., Victor, A., Pompili, V.J.,
Laughlin, M.J. Case Western Reserve University, Cleveland, OH.
Whether significant differences in biological potency of
CD1331 stem cells exist between those from patients with stable
coronary ischemia compared to those from healthy controls or
